Artículo

Control of pyrethroid-resistant populations of Triatoma infestans, the main vector of Trypanosoma cruzi, by treating dogs with fluralaner in the Argentine Chaco

Laiño, Mariano Alberto Icon; Cardinal, Marta Victoria Icon; Gaspe, Maria Sol Icon; Enriquez, Gustavo Fabián Icon; Alvedro, Alejandra Icon; Macchiaverna, Natalia Paula Icon; Gurtler, Ricardo Esteban Icon

Otros responsables

Fecha

12/2021

Editorial

Wiley Blackwell Publishing, Inc

Revista

Medical and Veterinary Entomology

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0269-283X

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

We assessed whether fluralaner administered to outbred healthy dogs reduced or supressed site infestation and abundance of pyrethroid-resistant populations of Triatoma infestans Klug (Heteroptera: Reduviidae). We conducted a placebo-controlled before-and-after efficacy trial in 28 infested sites in Castelli (Argentine Chaco) over 10 months. All 72 dogs initially present received either an oral dose of fluralaner (treated group) or placebo (control group) at month 0 posttreatment (MPT). Preliminary results justified treating all 38 control-house dogs with fluralaner 1 month later, and 71 of 78 existing dogs at 7 MPT. Site-level infestation and triatomine abundance were evaluated using timed manual searches with a dislodging aerosol. In the fluralaner-treated group, infestation dropped significantly from 100% at baseline to 19% over 6–10 MPT whereas mean abundance fell highly significantly from 5.5 to 0.8–0.9 triatomines per unit effort. In the placebo group, site infestation and mean abundance remained stable between 0 and 1 MPT, and strongly declined after fluralaner administration from 13.0−14.7 - triatomines at 0–1 MPT to 4.0–4.2 over 6–10 MPT. Only one of 81 noninfested sites before fluralaner treatment became infested subsequently. Fluralaner significantly reduced the site-level infestation and abundance of pyrethroid-resistant T. infestans and should be tested more widely in Phase III efficacy trials.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa